SISCAPA + Biognosys:

Enabling Scalable, Regulated Protein Biomarker Assays

SISCAPA has joined forces with Biognosys, a global leader in next-generation proteomics CRO services, to make its powerful immuno-mass spectrometry assays broadly accessible in regulated environments. This strategic collaboration enables pharmaceutical and biotechnology companies to access the full menu of validated SISCAPA assays—along with custom assay development capabilities—through Biognosys’ state-of-the-art infrastructure and proven expertise in large-scale, compliant study execution.

By combining SISCAPA’s highly specific immuno-enrichment with the precision of targeted mass spectrometry, the platform delivers sensitive, multiplexed, and unequivocally identifiable measurements of protein biomarkers in complex biological samples. With built-in calibratability using stable isotope-labeled standards, the assays offer unmatched reproducibility—critical for clinical development and regulatory submission.

Through this partnership, SISCAPA assays can now be deployed across the full drug development pipeline, from preclinical studies using cross-species-compatible assays to clinical trials requiring robust PK/PD and biomarker readouts. Biognosys provides the operational capacity and regulatory rigor needed to execute studies at scale, while SISCAPA ensures each assay meets the highest standards of analytical performance.

Together, SISCAPA and Biognosys are removing barriers to adoption by offering a seamless, end-to-end solution for translational and clinical biomarker quantification—accelerating the path from discovery to impact.